Lv2
146 积分 2023-12-21 加入
Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial
21天前
已完结
Dose-response characterization: A key to success in drug development
21天前
已完结
Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial
23天前
已完结
Concordance of Exposure Changes Because of Renal Impairment Between Results of Dedicated Renal Impairment Studies and Population Pharmacokinetic Predictions
23天前
已完结
Rationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide in patients with chronic kidney disease
1个月前
已完结
Pharmacokinetic‐pharmacodynamic (PK/PD) modelling of cotadutide effect in patients with chronic kidney disease and type 2 diabetes mellitus
1个月前
已完结
GLP-1 receptor agonists and GIP/GLP-1 co-agonists in the treatment of obesity in adolescents and the elderly
1个月前
已关闭
Agonistas del receptor GLP-1 y co-agonistas GIP/GLP-1 en el tratamiento de la obesidad en adolescentes y ancianos
1个月前
已完结
GLP-1-based therapies for diabetes, obesity and beyond
1个月前
已完结
Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial
1个月前
已完结
皖公网安备34019202002308
